Croatia's Halmed finds GMP deficiencies at Dhanuka Labs' antibiotic API plant

By Gareth Macdonald

- Last updated on GMT

Dhanuka Laboratories facility in Gurgaon
Dhanuka Laboratories facility in Gurgaon

Related tags Active pharmaceutical ingredients Active ingredient

An API plant operated by Dhanuka Laboratories does not comply with good manufacturing practices according to Croatian regulators.

According to a post​ on EudraGMP, inspectors who visited the facility in Gurgaon, India in February observed 32 deficiencies from EU GMP standards, including critical problems with quality assurance protocols, documentation and materials management.

The plant makes antibiotic active pharmaceutical ingredients (APIs), including the cephalosporin cefixime which is on the World Health Organisation’s (WHO) essential medicines list.

The Halmed inspectors said: “The QA system implemented on site, which related to the workshops that were engaged in the manufacture of cefixime, was found to be weak and not capable of proper design, planning, implementation, maintenance and continuous improvement."

Other deficiencies observed by the inspectors included potential contamination risk in chemical intermediates areas, problems with how raw materials are handled and failure to qualify instruments in the site’s analytical laboratory.

GMP withdrawal 

The Croatian agency described the violations as "very severe​" and said they pose a risk to patient health. It also recommended that the site’s GMP certificate – GIF-IW-N-4022/161/13 which was issued by Polish inspectors in 2013 – be withdrawn immediately.

Halmed also urged the European Directorate for the Quality of Medicines (EDQM) to suspend three certificates of suitability to the European Pharmacopoeia CEPs issued to Dhanuka and said “no further batches to be supplied to the market.​”

Dhanuka did not respond to a request for comment ahead of publication.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more